Publication | Closed Access

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

Urological ResearchUrologyVoiding DysfunctionMedicineAssess 12-Month SafetyPharmacotherapyActive-controlled Phase 3PharmacologyOveractive Bladder